Article Text
Abstract
This article examines the implicit promises of fairness in evidence based medicine (EBM), namely to avoid discrimination through objective processes, and to distribute effective treatments fairly. The relationship between EBM and vulnerable groups (such as those disadvantaged by virtue of poverty, ethnicity, age, gender, mental health problems or similar) is examined. Several aspects of EBM are explored: the way evidence is created (commissioning and design of, and participation in research), and the way evidence is applied in clinical care and health policy. This analysis suggests that EBM turns our attention away from social and cultural factors that influence health and focuses on a narrow biomedical and individualistic model of health. Those with the greatest burden of ill health are left disenfranchised, as there is little research that is relevant to them, there is poor access to treatments, and attention is diverted away from activities that might have a much greater impact on their health.
- evidence based medicine
- ethics
- justice
- vulnerable groups
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes, and interviews
- NICE is dead; long live NICE
- Addressing ethical challenges in HIV prevention research with people who inject drugs
- Updated 2018 NICE guideline on pharmacological treatments for people with ADHD: a critical look
- NICE may fail to stop “postcode prescribing,” MPs told
- Testing relationships: ethical arguments for screening for type 2 diabetes mellitus with HbA1C
- NICE: faster access to modern treatments? Analysis of guidance on health technologies
- From guidance to practice: Why NICE is not enough
- Methylphenidate for ADHD rejected from the WHO Essential Medicines List due to uncertainties in benefit-harm profile
- NICE recommendations for the assessment of stable chest pain: assessing the early economic and service impact in the rapid-access chest pain service